

Renaud Sabatier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5182294/publications.pdf>

Version: 2024-02-01

67
papers

2,596
citations

279798

23
h-index

214800

47
g-index

80
all docs

80
docs citations

80
times ranked

4419
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. <i>Cancers</i> , 2022, 14, 354.	3.7	5
2	Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNETâ€”a phase I, single-arm study. , 2022, 10, e003777.		141
3	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. <i>Molecular Oncology</i> , 2022, 16, 2057-2070.	4.6	4
4	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	3.7	0
5	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021, 13, 140.	3.7	4
6	Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1272.	2.4	1
7	The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2021, 161, 166-172.	1.4	7
8	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021, 13, 87.	8.2	24
9	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 632.	3.2	30
10	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. <i>Gynecologic Oncology</i> , 2021, 163, 64-71.	1.4	3
11	Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. <i>Future Oncology</i> , 2021, 17, 3781-3785.	2.4	18
12	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021, 159, 205-214.	2.8	7
13	Prediction of early discharge after gynaecological oncology surgery within ERAS. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 1985-1993.	2.4	9
14	LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. <i>Annals of Oncology</i> , 2020, 31, S1166.	1.2	25
15	Clinical Activity and Safety of the Antiâ€”Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repairâ€”Deficient Endometrial Cancer. <i>JAMA Oncology</i> , 2020, 6, 1766.	7.1	229
16	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. <i>Cancers</i> , 2020, 12, 1573.	3.7	25
17	Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. <i>Gynecologic Oncology</i> , 2020, 157, 29-35.	1.4	24
18	Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer. , 2020, 80, .		0

#	ARTICLE	IF	CITATIONS
19	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	3.7	160
20	Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSÃ© phase II trial. <i>Annals of Oncology</i> , 2019, 30, 1985-1991.	1.2	128
21	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. <i>Cancers</i> , 2019, 11, 774.	3.7	23
22	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	2.4	5
23	High Response to Cetuximab in a Patient With <i>EGFR</i> -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	5
24	Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	0
25	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 403-412.	2.4	39
26	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 494-500.	1.0	18
27	Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 281-283.	1.0	14
28	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	3.7	40
29	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1226-1237.	3.0	10
30	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 307-316.	2.5	16
31	Value of Dynamic Contrast-enhanced and Diffusion-weighted MR Imaging in the Detection of Pathologic Complete Response in Cervical Cancer after Neoadjuvant Therapy: A Retrospective Observational Study. <i>Radiology</i> , 2017, 284, 432-442.	7.3	49
32	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 28-36.	2.8	48
33	Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2017, 84, 34-43.	2.8	24
34	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. <i>European Journal of Cancer</i> , 2017, 81, 138-141.	2.8	1
35	Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. <i>Journal of Cancer</i> , 2016, 7, 2077-2084.	2.5	6
36	High-dose chemotherapy for inflammatory breast cancer: impact of immunohistochemical status on survival outcome. <i>Annals of Oncology</i> , 2016, 27, vi93.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1082-1086.	2.4	13
38	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. <i>Breast</i> , 2016, 27, 8-14.	2.2	5
39	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. <i>British Journal of Cancer</i> , 2016, 115, 1024-1031.	6.4	23
40	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. <i>Familial Cancer</i> , 2016, 15, 497-506.	1.9	10
41	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. <i>European Journal of Cancer</i> , 2016, 57, 118-126.	2.8	5
42	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016, 7, 79428-79441.	1.8	11
43	Abstract P4-13-23: Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH) and patient-derived tumor xenograft (PDX) for precision medicine in advanced breast cancer: A single-center prospective study. , 2016, , .		0
44	Abstract 2036: A phase Ib pharmacokinetic drug-drug interaction evaluation of oral buparlisib in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer (MBC). , 2016, , .		0
45	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 293-9.	1.1	7
46	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. <i>BMC Cancer</i> , 2015, 15, 697.	2.6	3
47	Prognostic Factors for Ovarian Epithelial Cancer in the Elderly. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 815-822.	2.5	29
48	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015, 6, 5449-5464.	1.8	424
49	Carcinomatous Myelitis and Meningitis after a Squamous Cell Carcinoma of the Lip. <i>Case Reports in Oncology</i> , 2014, 7, 33-38.	0.7	3
50	586 Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors. <i>European Journal of Cancer</i> , 2014, 50, 189.	2.8	0
51	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. <i>Molecular Cancer</i> , 2014, 13, 228.	19.2	91
52	Personalized medicine: Present and future of breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 223-233.	4.4	49
53	“Stealth” tumors. <i>Oncolmmunology</i> , 2012, 1, 366-368.	4.6	14
54	Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?. <i>Annals of Oncology</i> , 2012, 23, 714-721.	1.2	56

#	ARTICLE	IF	CITATIONS
55	Are there candidates for high-dose chemotherapy in ovarian carcinoma?. Journal of Experimental and Clinical Cancer Research, 2012, 31, 87.	8.6	7
56	A seven-gene prognostic model for platinum-treated ovarian carcinomas. British Journal of Cancer, 2011, 105, 304-311.	6.4	37
57	Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ? : A monocentric institution safety analysis of 46 patients. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 125-131.	1.5	6
58	Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. European Journal of Cancer, 2011, 47, 1537-1545.	2.8	26
59	A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 2011, 126, 407-420.	2.5	231
60	Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2011, 127, 273-281.	2.5	66
61	Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, 2011, 10, 86.	19.2	46
62	Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. PLoS ONE, 2011, 6, e27656.	2.5	143
63	Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer, 2010, 10, 645.	2.6	28
64	<i>BARD1</i> homozygous deletion, a possible alternative to <i>BRCA1</i> mutation in basal breast cancer. Genes Chromosomes and Cancer, 2010, 49, 1143-1151.	2.8	23
65	The CINSARC signature: Prognostic and predictive of response to chemotherapy?. Cell Cycle, 2010, 9, 4025-4027.	2.6	12
66	Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): A prospective observational analysis.. Journal of Clinical Oncology, 2010, 28, e15013-e15013.	1.6	4
67	Gene expression profiling and prediction of clinical outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, 2009, 72, 98-109.	4.4	34